Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01459614
First received: October 24, 2011
Last updated: May 30, 2014
Last verified: May 2014

October 24, 2011
May 30, 2014
November 2011
October 2015   (final data collection date for primary outcome measure)
Primary Outcome Measure [ Time Frame: at 6 months ] [ Designated as safety issue: Yes ]
To assess the efficacy of the combination of gemcitabine, taxotere, and xeloda (GTX) with cisplatin in subjects with metastatic pancreatic cancer based on the progression-free survival (PFS) rate at 6 month.
Primary Outcome Measure [ Time Frame: Continous ] [ Designated as safety issue: Yes ]
To assess the efficacy of the combination of gemcitabine, taxotere, and xeloda (GTX) with cisplatin in subjects with metastatic pancreatic cancer based on the progression-free survival (PFS) rate at 6 month.
Complete list of historical versions of study NCT01459614 on ClinicalTrials.gov Archive Site
  • Secondary Outcome Measure: To assess safety and characterize toxicities of the combination of GTX with cisplatin in subjects with metastatic pancreatic cancer [ Time Frame: 1.5 Years ] [ Designated as safety issue: Yes ]
  • Secondary Outcome Measure: To estimate 3, 6, 9, 12, 15, and 18 month disease control rate (DCR), PFS, and overall survival (OS). [ Time Frame: 1.5 years ] [ Designated as safety issue: Yes ]
  • Secondary Outcome: To estimate a PFS rate of an expansion cohort testing an alternative schedule [ Time Frame: 1.5 ] [ Designated as safety issue: Yes ]
  • Secondary Outcome Measure: To assess safety and characterize toxicities of the combination of GTX with cisplatin in subjects with metastatic pancreatic cancer [ Time Frame: 1.5 Years ] [ Designated as safety issue: Yes ]
  • Secondary Outcome Measure: To estimate 3, 6, 9, 12, 15, and 18 month disease control rate (DCR), PFS, and overall survival (OS). [ Time Frame: 1.5 years ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer
Phase II Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin in Subjects With Metastatic Pancreatic Cancer

Primary Objectives

To assess the efficacy of the combination of gemcitabine, taxotere, and xeloda (GTX) with cisplatin in subjects with metastatic pancreatic cancer based on the progression-free survival (PFS) rate at 6 month.

Secondary Objectives

  • To assess safety and characterize toxicities of the combination of GTX with cisplatin in subjects with metastatic pancreatic cancer.
  • To estimate 3, 6, 9, 12, 15, and 18 month disease control rate (DCR), PFS, and overall survival (OS).

Study Design

This study is a single arm phase II study to assess the efficacy of the combination of GTX and cisplatin in subjects with metastatic pancreatic cancer. Approximately 28 evaluable subjects will be enrolled. Subjects will be considered efficacy evaluable if they complete at least one cycle of treatment and an assessment of progression status can be made at 6 months. Subjects who drop out of the study due to reasons other than disease progression, death, or limiting toxicity (defined in section 4.3) may be replaced. Subjects whose death is unequivocally accidental and unrelated to cancer or its treatment may also be replaced.

The study will have a safety run-in phase consisting of 6 subjects. There is no previous experience with this treatment combining GTX and cisplatin. Therefore, to ensure that the combination is safe, the first six subjects will be treated at DL1 (Table 1) and observed for limiting toxicity (defined in section 4.3) for the first 2 cycles before continuation with further accrual. If ≤ 2 limiting toxicity events occur in the first 6 patients, we will proceed with additional accrual at DL1 to complete a total of 12 patients in stage 1. If > 2 limiting toxicity events occur among the first 6 patients, we will suspend DL1 and enroll 6 patients at lower dose (DL-1). If ≤ 2 limiting toxicity events occur, we will proceed with additional accrual at DL-1 to complete a total of 12 patients in stage 1. If > 2 limiting toxicity events occur, we will suspend the study pending data review. After the safety run-in, the study will be continuously monitored for adverse events using a Bayesian toxicity monitoring rule (Section 12).

The primary endpoint will be the PFS rate at 6 month, which is defined as the proportion of subjects alive, free of disease progression at 6 months. The treatment regimen would be considered of insufficient activity for further study in this population if PFS rate at 6 months is 50% or less, and the minimum required level of efficacy that would warrant further study with the proposed regimen is a 75% PFS rate at 6 months. The study design includes interim monitoring for futility using a predictive probability approach. We will stop the study early if given the information at the interim analysis, it is unlikely that the PFS rate at 6 months will be greater than 50% if the study continues to the end (Section 12).

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Pancreatic Cancer
  • Drug: Gemcitabine
    IV at 10mg/m2/min (50 minutes for 500mg/m2) on Days 4 and 11
  • Drug: Taxotere
    IV on Days 4 and 11
    Other Name: Docetaxel
  • Drug: Xeloda
    orally, twice a day Days 1-14
    Other Name: Capecitabine
  • Drug: Cisplatin
    IV Days 4 and 11
    Other Names:
    • Platinol
    • CDDP
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
43
Not Provided
October 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 1. Subjects must have histologically or cytologically confirmed metastatic pancreatic adenocarcinoma. Subjects with islet cell neoplasms are excluded. Subjects with mixed histology will be excluded.
  • 2. Subject has one or more tumors measurable by CT scan using RECIST 1.1 criteria. MRI is acceptable if a CT scan is contraindicated.
  • 3. Patient must be chemotherapy naïve or must have completed chemotherapy greater than 5 years prior to enrollment.
  • 4. Male or non-pregnant and non-lactating female of age >18 years
  • 5. ECOG performance status <1. ECOG 0 indicates that the patient is fully active and able to carry on all pre-disease activities without restriction; and, ECOG 1 indicates that the patient is restricted in physically strenuous activity but is ambulatory and able to carry out work of a light or sedentary nature
  • 6. Life expectancy of greater than 12 weeks.
  • 7. Subjects must have adequate organ and marrow function as defined below: WBC ≥ 3,500/mcL Absolute Neutrophil Count ≥1,500/mcL Platelets ≥100 x 10^9/L Hemoglobin ≥ 9 g/d Total Bilirubin within normal institutional limits Alkaline phosphatase ≤ 2.5 x ULN (≤ 5 X ULN for subjects with documented liver metastases) AST(SGOT)/ALT(SGPT) ≤ 2.5 x ULN (≤ 5 X ULN for subjects with documented liver metastases) Creatinine within normal institutional limits OR Creatinine clearance ≥ 60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.
  • 8. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
  • 9. Willingness to undergo a tumor biopsy (implemented after the first 6 patients).
  • 10. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • 1. Subjects who have had any prior chemotherapy within 5 years of enrollment
  • 2. Subjects who have had radiotherapy for pancreatic cancer.
  • 3. Age ≥ 76 years
  • 4. Subjects who are receiving or have received any other investigational agents within 28 days prior to Day 1 of treatment in this study.
  • 5. Subject has undergone major surgery, other than diagnostic surgery (i.e.--surgery done to obtain a biopsy for diagnosis or an aborted Whipple), within 28 days prior to Day 1 of treatment in this study.
  • 6. Subject has known brain metastases unless previously treated and well controlled for at least 3 months (defined as stable clinically, no edema, no steroids).
  • 7. History of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, taxotere, xeloda, or cisplatin.
  • 8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • 9. Subject has serious medical risk factors involving any of the major organ systems such that the Investigator considers it unsafe for the subject to receive an experimental research drug.
  • 10. Subject has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
  • 11. Subject has a known history of infection with HIV, hepatitis B, or hepatitis C.
  • 12. Subject is pregnant or breast feeding.
  • 13. Subject is unwilling or unable to comply with study procedures.
  • 14. Subject with an unhealed surgical wound or other clinically significant wound.
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01459614
J11125, Swim Across America Laboratory
No
Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center
Not Provided
Principal Investigator: Dung Le, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP